Newsquawk Logo

Eli Lilly’s (LLY) US prescriptions for Zepbound were 1,390 for the week ended April 10, according to IQVIA data

Eli Lilly's recent prescription figures for Zepbound indicate early interest in the product, but the 1,390 prescriptions reported may require context to evaluate their significance against broader expectations or past performance.

Newsquawk StaffPublished On the live feed at — 6 more headlines followed before this page went public
Newsquawk headlinesUTC

UK PM Starmer said he was furious he was not told Mandelson had failed a security vetting when he was appointed; A Labour backbencher has said it “doesn’t sound credible” that Keir Starmer was unaware Peter Mandelson had failed his security vetting.

Changan is reportedly weighing setting up a Spanish auto plant; yet to make a decision

Eli Lilly’s (LLY) US prescriptions for Zepbound were 1,390 for the week ended April 10, according to IQVIA data

Germany’s coalition is said to be at odds over the size of the government’s stake in KfW, Bloomberg reports

EU Commission Spokesperson says the EU is to prep a joint action on jet fuel, if the Strait of Hormuz blockage persists

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
Context

If this aligns with or exceeds expectations, it could bode well for Eli Lilly’s revenue outlook in the pharmaceutical sector, while a shortfall may raise questions about the drug's market acceptance. Investors should monitor subsequent weeks' data for trend confirmation and potential impacts on stock performance.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.